cb03-154
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 2, 2022 (NCT05499260)
Timeline
Indications
Mechanism of action
Voltage-gated potassium channel, KQT; KCNQ2(Kv7.2)/KCNQ3(Kv7.3) agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07082192 | Phase 2/Phase 3 (Phase 3) | Sep 29, 2025 | Shanghai Zhimeng Biopharma, Inc. |
| NCT07238868 | Phase 2 | Aug 14, 2025 | Shanghai Zhimeng Biopharma, Inc. |
| NCT06612775 | Phase 2 | Sep 30, 2024 | Shanghai Zhimeng Biopharma, Inc. |
| NCT05502549 | Phase 1 | Oct 31, 2022 | Nucleus Network Ltd, Shanghai Zhimeng Biopharma, Inc. |
| NCT05499260 | Phase 1 | May 2, 2022 | Frontage Laboratories, Inc., Shanghai Zhimeng Biopharma, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Zhimeng Biopharma, Inc. | For profit | 5 | 5 | 3 | 2022 |
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2022 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1